GLP-1 RECEPTOR AGONIST · ELI LILLY · WEEKLY INJECTION
Trulicity®
dulaglutide · 0.75 mg → 4.5 mg · Subcutaneous injection
GLP-1 receptor agonist approved for type 2 diabetes management and cardiovascular risk reduction in adults with established CVD or multiple CV risk factors. PA required by most major payers.
Type 2 Diabetes
Cardiovascular Risk Reduction